A closeup of a female scientist in the lab

The future of HIV care

We asked

What if the immune system could control HIV like other chronic infections?

Through gene therapy, we believe it can.

Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

Our lentiviral technology harnesses HIV’s efficient cell entry and DNA manipulation to deliver protective capabilities directly to the nucleus of T cells.

Three steps to protect against HIV.

Our approach to CD4 T Cell modification.

01

Preventing HIV Binding

HIV binds to using embedded in the virus surface. CCR5 expression is crucial for HIV’s entry into human cells. The virus uses CCR5, a protein on the surface of white blood cells, as a key co-receptor for entering target immune cells.

The contains the DNA of the immune cell, and what we are trying to avoid is allowing HIV to install new DNA in the nucleus. This would increase the spread of HIV in the body and can eventually lead to AIDS.

By blocking CCR5, we hope to make the cell resistant to HIV’s entry, thereby preventing new infections.

Learn more about CCR5 removal.

2 1 3

Glycoprotein

A biomolecule consisting of a protein linked to one or more carbohydrate chains. These molecules play crucial roles in various biological processes, including cell signaling, recognition, and immune response.

CD4+ T-Cell

Also known as a helper T cell, a white blood cell crucial for coordinating immune responses. Recognizing antigens, these cells activate other immune cells to mount effective responses against infections.

Nucleus

Contains DNA that carries the genetic instructions used in the development and functioning of all known living organisms and many viruses. If we can prevent HIV DNA from getting here, this cell will stay healthy and continue to do its job of fighting HIV.

Capsid

The protein coat surrounding the genetic material of a virus, providing protection and aiding in its attachment to host cells during infection.

CCR5

A protein receptor on the surface of certain immune cells.

TAT Protein

A regulatory protein found in certain viruses that plays a crucial role in the virus's replication by facilitating the transcription of viral RNA into messenger RNA (mRNA) within the host cell.

miRNA

A short RNA molecule that can selectively inhibit the expression of specific genes, often used in the regulation of gene activity for research or therapeutic purposes. We deliver miRNA to the nucleus of T cells to make them less susceptible to the virus.

HIV

Human Immunodeficiency Virus is a retrovirus that attacks the immune system, specifically CD4 cells (T cells), weakening the body's ability to fight off infections and diseases. If left untreated, HIV can progress to the advanced stage known as AIDS (Acquired Immunodeficiency Syndrome).

AGT-103

A gene therapy using miRNA to block two HIV-specific genes, to help stop further replication of the virus.

02

Inhibiting HIV Replication

Once it binds, HIV and the CD4 T cell fuse together, allowing the HIV to infect the cell with genetic material. HIV then inserts itself into the DNA of the CD4 T cell, to enable replication.

If the cell is already infected with HIV, additional miRNAs in AGT103-T target highly-conserved sites in the HIV genome to help stop further replication of the virus.

Learn more about HIV infection

03

Our Solution

Using our proprietary lentiviral technology, we are leveraging this same mechanism to deliver modifying miRNAs to a person’s CD4 T cells, which we believe will help them become resistant to HIV’s entry and propagation of infection.

Learn more about our progress

Our Pipeline

Early Discovery i
Preclinicali
Ph Iai
Ph Ibi
Ph IIi
AGT103-T
AGT103-T Vaccine
AGT103-T+
AGT104-T sCD4
AGT105-T
Discoveryi
Analytical Validationi
Clinical Validationi
Commercial Launchi
AGT103-T SEQ

AGT-103-T

Phase Ia

AGT-103-T Vaccine

Preclinical

AGT-103-T+

Preclinical

AGT-104-TsCD4

Preclinical

AGT-105-T

Early Discovery

AGT-103-T SEQ

Early Discovery

Backed by a robust patent portfolio.

Our HIV technologies are covered by an extensive patent portfolio. DLA Piper Global Law Firm and Snell and Wilmer serve as our patent counsel.

CEO Jeff Galvin standing in front of a wall of patent plaques

Publications